The Magazine for Sleep Professionals
Monday, September 28, 2026
Noctrix Health, Inc., the developer of the Nidra® Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS), announced a significant expansion of private financing to accelerate its U.S. commercial launch. The company also announced several key leadership appointments to strengthen its commercial and scientific teams. Financing Update Noctrix Health […]
A pediatric sleep specialist at Seattle Children’s Hospital, Lourdes DelRosso, MD, PhD, had long noted that many parents would come to a consultation with concerns that their children “moved a lot in their sleep, were tired during the day, or had problems in school.” The parents attributed the daytime symptoms […]
A new clinical practice guideline developed by the American Academy of Sleep Medicine provides updated recommendations for the treatment of restless legs syndrome. The guideline reflects the latest scientific evidence and recommends significant changes in the standard treatment of RLS in adults. Available online as an accepted paper in the […]
Noctrix Health, Inc. announced that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation, with strong support from insiders, including OrbiMed and Treo Ventures. This infusion of capital will propel the advancement […]
Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of restless legs syndrome (RLS). The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center, randomized, sham-controlled clinical trial, and a subsequent […]
